News articles about Allergan (NYSE:AGN) have trended somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Allergan earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.2293988501593 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
Allergan stock traded down $1.80 during mid-day trading on Friday, reaching $158.43. The company’s stock had a trading volume of 2,501,792 shares, compared to its average volume of 2,906,322. Allergan has a 12-month low of $142.81 and a 12-month high of $256.80. The firm has a market capitalization of $53.72 billion, a price-to-earnings ratio of 9.69, a P/E/G ratio of 1.13 and a beta of 1.17. The company has a current ratio of 1.10, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.
Allergan (NYSE:AGN) last released its quarterly earnings results on Monday, April 30th. The company reported $3.74 EPS for the quarter, beating analysts’ consensus estimates of $3.36 by $0.38. The firm had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.59 billion. Allergan had a negative net margin of 11.94% and a positive return on equity of 8.53%. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the previous year, the business earned $3.35 EPS. equities research analysts forecast that Allergan will post 16.03 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 15th. Stockholders of record on Friday, May 18th will be given a dividend of $0.72 per share. The ex-dividend date is Thursday, May 17th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.82%. Allergan’s dividend payout ratio (DPR) is currently 17.61%.
Several equities research analysts have recently issued reports on AGN shares. Vetr lowered shares of Allergan from a “hold” rating to a “sell” rating and set a $180.97 price target for the company. in a research note on Monday, January 22nd. Bank of America raised their price target on shares of Allergan from $208.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Cantor Fitzgerald set a $191.00 price target on shares of Allergan and gave the stock a “hold” rating in a research note on Friday, April 27th. ValuEngine lowered shares of Allergan from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Deutsche Bank set a $210.00 price target on shares of Allergan and gave the stock a “buy” rating in a research note on Tuesday, May 1st. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the stock. Allergan currently has a consensus rating of “Hold” and a consensus target price of $214.81.
In other news, insider Maria Teresa Hilado purchased 895 shares of Allergan stock in a transaction dated Thursday, March 15th. The stock was purchased at an average cost of $167.39 per share, for a total transaction of $149,814.05. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Joseph H. Boccuzi purchased 900 shares of Allergan stock in a transaction dated Monday, March 5th. The shares were purchased at an average price of $143.42 per share, with a total value of $129,078.00. The disclosure for this purchase can be found here. Insiders have bought a total of 8,095 shares of company stock valued at $1,258,081 over the last 90 days. Company insiders own 0.36% of the company’s stock.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.